Nova Eye Medical : Investor Presentation March 2023

Investor Presentation

Nova Eye Medical Limited (ASX:EYE)

March 2023

Addressing the two leading causes of blindness in the developed world

Disclaimer

This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward- looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medical (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. It is also not intended to inform or guide clinical decisions.

nova-eye.com| 2

ASX: EYE Financials and Corporate Snapshot

Nova Eye Medical Limited

Australian Securities

Exchange

ASX

146M1

Shares on Issue

A$34M1

Market Capitalisation

EYE	9%1
Ticker	Management + Board
	Ownership (fully diluted)

A$15.2M2	A$24.9M2
Revenues	Net Assets
(based on 12 months)

A$3.6M2

Cash

(Including tax refund of $1.1m received on 6 January 2023)

1	As at 24 February 2023	nova-eye.com| 3
2	As at 31 December 2022

Executive Summary

• Nova Eye pioneered the fastest growing segment in the burgeoning ophthalmic market; canal surgery for glaucoma, and holds over 100 patents in this domain
• Nova Eye is one of three principal participants in the canal surgery segment with a forecast segment CAGR of 19% over the five years to 2027
• Nova Eye has invested in developing a next generation product (iTrackTM Advance) that has been applauded in trials with leading KOLs
• FDA market clearance for iTrackTM Advance is expected in the coming weeks and Nova Eye expects to win significant market share
• Proceeds from the share placement will be used for
• • expansion of the glaucoma surgical device business in the USA, Europe and China through additional sales representatives, marketing and surgeon training.
  • investment in production processes to reduce production costs.
  • corporate costs and general working capital including the AlphaRET business

nova-eye.com| 4

ASX: EYE Business Snapshot

Focused on vision and flighting blindness, Nova Eye Medical leads the way in glaucoma and age-related macular degeneration, the leading causes of blindness in the developed world.

Nova Eye Medical, Glaucoma

Strategy	Develop, market and sell comprehensive portfolio
of glaucoma consumable surgical devices
Market	Canal Surgery segment of the glaucoma surgical devices
market scheduled to grow rapidly over 2022 to 2027
Sales	Established infrastructure; direct sales in USA, Germany,
Australia; +20 distributors
Manufacturing	California, USA and Dunedin, New Zealand
IP Status
>100 patents issued and pending
Regulatory
Clearance in all key global markets
Reimbursement
Favorable CPT codes with/without cataract surgery (USA)

AlphaRET, AMD

Strategy	Progress 2RT® to market-ready status with
partner for confirmatory study
Market	Intermediate Age-related Macular Degeneration
treatment (iAMD) - market not addressed
Sales	Sales program to coincide with partnering
Manufacturing	Adelaide, Australia based contract manufacturing
IP Status	First mover advantage, >10 patents issued and
pending in major markets
Regulatory	CE Mark (iAMD and diabetic eye disease) in
Europe, Australia, NZ and FDA (diabetic eye
	disease only) in USA
Reimbursement	Pending

nova-eye.com| 5